Initial Treatment Outcomes of Radiofrequency Ablation for Papillary Thyroid Microcarcinoma at Bach Mai Hospital
Main Article Content
Abstract
Abstract
Objective: To evaluate the initial outcomes of radiofrequency ablation (RFA) for the treatment of papillary thyroid microcarcinoma (PTMC) at Bach Mai Hospital.
Subjects and methods: A retrospective and prospective cross-sectional descriptive study was conducted on all patients who underwent RFA for PTMC at Bach Mai Hospital between October 1, 2022, and December 31, 2024. All patients were followed for a minimum of 6 months after the procedure.
Results: The study included 35 patients (3 males and 32 females) with a mean age of 45,71 ± 14,00 years (range: 24–75). The mean tumor volume was 0,064 ± 0,079 mL. All patients underwent RFA for PTMC. The mean follow-up duration was 16,29 ± 8,04 months. The complete disappearance rate of tumors increased over time: 0% at 3 months, 14,3% at 6 months, 31,8% at 12 months, 81,8% at 18 months, and 100% at 24 months of follow-up. Only one patient (2,8%) experienced transient hoarseness; no delayed complications or permanent injuries were observed.
Conclusion: Radiofrequency ablation is a minimally invasive, effective, and safe treatment option for papillary thyroid microcarcinoma.
Keywords
radiofrequency ablation, RFA, papillary thyroid microcarcinoma, PTMC, minimally invasive treatment
Article Details
References
2. Yoshida Y, Horiuchi K, Okamoto T. Patients’ View on the Management of Papillary Thyroid Microcarcinoma: Active Surveillance or Surgery. Thyroid. 2020;30 (5):681-687. doi:10.1089/thy.2019.0420
3. Jung SL, Baek JH, Lee JH, et al. Efficacy and Safety of Radiofrequency Ablation for Benign Thyroid Nodules: A Prospective Multicenter Study. Korean Journal of Radiology. 2018;19 (1):167-174. doi:10.3348/kjr.2018.19.1.167
4. Khalilzadeh O, Baerlocher MO, Shyn PB, et al. Proposal of a New Adverse Event Classification by the Society of Interventional Radiology Standards of Practice Committee. Journal of Vascular and Interventional Radiology.2017;28 (10):1432-1437.e3. doi:10.1016/j.jvir.2017.06.019
5. Jeong SY, Baek SM, Shin S, Son JM, Kim H, Baek JH. Radiofrequency Ablation of Low-Risk Papillary Thyroid Microcarcinoma: A Retrospective Cohort Study Including Patients with More than 10 Years of Follow-up. Thyroid®.2025;35 (2):143-152. doi:10.1089/thy.2024.0535
6. Cho SJ, Baek SM, Lim HK, Lee KD, Son JM, Baek JH. Long-Term Follow-Up Results of Ultrasound-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: More Than 5-Year Follow-Up for 84 Tumors. Thyroid. 2020;30 (12):1745-1751. doi:10.1089/thy.2020.0106
7. LiVolsi VA. Papillary thyroid carcinoma: an update. Mod Pathol. 2011;24 Suppl 2:S1-9. doi:10.1038/modpathol.2010.129
8. Choi Y, Jung SL. Efficacy and Safety of Thermal Ablation Techniques for the Treatment of Primary Papillary Thyroid Microcarcinoma: A Systematic Review and Meta-Analysis. Thyroid®. 2020;30 (5):720-731. doi:10.1089/thy.2019.0707
9. Lim HK, Cho SJ, Baek JH, et al. US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population. Korean J Radiol. 2019;20 (12):1653-1661. doi:10.3348/kjr.2019.0192